Drugs / Insulin, Regular, Human
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04739371 | Jun 2021 → Jun 2022 | acute insulin response | Pennington Biomedical Research Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin, Regular, Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04739371 ↗ |
| Route | Intranasal | “40 participants will receive 40 IUs of intranasal insulin about 30 minutes before consuming an ad libitum lunch.” NCT04739371 ↗ |